Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers

Pharmacology

Volumn 91, Issue 1-2, 2013, Pages 35-38

  Riccioni, G ^a   Prencipe, G ^a   Benvenuto, A ^b   Masciocco, L ^b   Ventra, S ^c   Rizzo, U ^d   Russi, C ^e   Speziale, G ^c  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b Lastaria Hospital   (Italy)

^c Anthea Hospital   (Italy)

^d Santa Rita Hospital   (Italy)

^e Paediatric Allergy Service   (Italy)

Author keywords

Atenolol; Bisoprolol; Carvedilol; Chronic stable angina pectoris; Ivabradine; SF 36; Blockers

Indexed keywords

ATENOLOL; BISOPROLOL; CARVEDILOL; IVABRADINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; EXERCISE; FEMALE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SINGLE BLIND PROCEDURE; SOCIAL INTERACTION; STABLE ANGINA PECTORIS;

EID: 84868606229     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000343631     Document Type: Article

References (15)

1. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381
2. Savonitto S, Ardissino D. Selection of drug therapy in stable angina pectoris. Cardiovasc Drugs Ther 1998;12:197-210
3. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-357
4. Borer JS, Tardif JC. Efficacy of ivabradine, a selective If inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol 2010;105:29-35
5. Riccioni G. Ivabradine: recent and potential applications in clinical practice. Expert Opin Pharmacother 2011;12:443-450
6. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100:149-155
7. Savelieva I, Camm AJ. Novel If current inhibitor ivabradine: safety considerations. Adv Cardiol 2006;43:79-96
8. Tardif JC, Ponikowski T, Kahan T, ASSOCIATE Study investigators: Efficacy of If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540-548
9. Hjemdahl P, Wiklund IK. Quality of life on antihypertensive drug therapy: scientific end-point or marketing exercise?. J Hypertens 1992;10:1437-1447
10. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-164
11. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators: Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomized, double-blind, placebocontrolled trial. Lancet 2008;372:807-816
12. Tardif JC, Ford I, Tendera M, Bourassa, Fox K, INITIATIVE Investigators: Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536
13. Koster R, Kaehler J, Meinertz T, REDUCTION Study Group: Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J 2009;158:e51-e57
14. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003;284:676-682
15. Tardif JC, Ponikowski T, Kahan T. for the ASSOCIATE Study investigators: Efficacy of If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;26:2529-2536